What happens if I overdose Sildenafil Citrate?
Contact 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center, or emergency room immediately.
Proper storage of Sildenafil Citrate:
Sildenafil Citrate is usually handled and stored by a health care provider. If you are using Sildenafil Citrate at home, store Sildenafil Citrate as directed by your pharmacist or health care provider. Keep Sildenafil Citrate out of the reach of children and away from pets.
Overdose of Sildenafil Citrate in details
In single dose volunteer studies of doses up to 800 mg, adverse reactions were similar to those seen at lower doses, but the incidence rates and severities were increased. Doses of 200 mg did not result in increased efficacy but the incidence of adverse reactions (headache, flushing, dizziness, dyspepsia, nasal congestion, altered vision) was increased.
Treatment: In cases of overdose, standard supportive measures should be adopted as required. Renal dialysis is not expected to accelerate clearance as Sildenafil Citrate is highly bound to plasma proteins and not eliminated in the urine.
What should I avoid while taking Sildenafil Citrate?
Grapefruit and grapefruit juice may interact with Sildenafil Citrate and lead to unwanted side effects. Avoid the use of grapefruit products while taking Sildenafil Citrate.
Drinking alcohol can increase certain side effects of Sildenafil Citrate.
Avoid using any other medicines to treat impotence, such as alprostadil or yohimbine, without first talking to your doctor.
Sildenafil Citrate warnings
Before taking Sildenafil Citrate it should be undertake a survey of the cardiovascular system.
This medication should be used with caution in patients with anatomical deformation of the penis (such as angulation, cavernous fibrosis or Peyronie's disease) and people with medical conditions that predispose to priapism (such as sickle cell anemia, multiple myeloma, or leukemia).
It should not be used in patients for whom sexual activity is contraindicated.
With caution ude Sildenafil Citrate in patients with a tendency to bleeding, gastric ulcer and duodenal ulcer in acute phase, with hereditary retinitis pigmentosa.
In experimental studies have not been found any evidence of carcinogenicity of Sildenafil Citrate. Bacterial and in vivo mutagenicity tests for the study were negative.
This drug is not used in patients under the age of 18 years.
Sildenafil Citrate has no effect on the ability to drive and control mechanisms.
What should I discuss with my healthcare provider before taking Sildenafil Citrate?
- If you have an allergy to Sildenafil Citrate or any other part of Sildenafil Citrate injection (PAH).
- If you are allergic to any drugs like this one, any other drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.
- If you use drugs called "poppers" like amyl nitrite and butyl nitrite.
- If you are taking any of these drugs: Isosorbide dinitrate, isosorbide mononitrate, nitroglycerin, riociguat, or ritonavir.
- If you are taking another drug that has the same drug in it.
- If you are taking or will be taking another drug like this one.
- If you have a health problem called pulmonary veno-occlusive disease (PVOD).
This is not a list of all drugs or health problems that interact with this medicine.
Tell your doctor and pharmacist about all of your drugs (prescription or OTC, natural products, vitamins) and health problems. You must check to make sure that it is safe for you to take Sildenafil Citrate injection with all of your drugs and health problems. Do not start, stop, or change the dose of any drug without checking with your doctor.
Sildenafil Citrate precautions
A medical history and physical examination should be undertaken to diagnose erectile dysfunction and determine potential underlying causes, before pharmacological treatment is considered.
Prior to initiating any treatment for erectile dysfunction, physicians should consider the cardiovascular status of their patients, since there is a degree of cardiac risk associated with sexual activity. Sildenafil Citrate has vasodilator properties, resulting in mild and transient decreases in blood pressure. Prior to prescribing Sildenafil Citrate, physicians should carefully consider whether their patients with certain underlying conditions could be adversely affected by such vasodilatory effects, especially in combination with sexual activity. Patients with increased susceptibility to vasodilators include those with left ventricular outflow obstruction (eg, aortic stenosis, hypertrophic obstructive cardiomyopathy), or those with the rare syndrome of multiple system atrophy manifesting as severely impaired autonomic control of blood pressure.
Sildenafil Citrate potentiates the hypotensive effect of nitrates. Serious cardiovascular events, including myocardial infarction, unstable angina, sudden cardiac death, ventricular arrhythmia, cerebrovascular haemorrhage, transient ischaemic attack, hypertension and hypotension have been reported post-marketing in temporal association with the use of Sildenafil Citrate. Most, but not all, of these patients had preexisting cardiovascular risk factors. Many events were reported to occur during or shortly after sexual intercourse and a few were reported to occur shortly after the use of Sildenafil Citrate without sexual activity. It is not possible to determine whether these events are related directly to these factors or to other factors. Agents for the treatment of erectile dysfunction, including Sildenafil Citrate, should be used with caution in patients with anatomical deformation of the penis (such as angulation, cavernosal fibrosis or Peyronie's disease), or in patients who have conditions which may predispose them to priapism (such as sickle cell anaemia, multiple myeloma or leukaemia).
The safety and efficacy of combinations of Sildenafil Citrate with other treatments for erectile dysfunction have not been studied.
Therefore, the use of such combinations is not recommended. Visual defects and cases of non-arteritic anterior ischaemic optic neuropathy have been reported in connection with the intake of Sildenafil Citrate and other PDE5 inhibitors. The patient should be advised that in case of sudden visual defect, he should stop taking Sildenafil Citrate and consult a physician immediately.
Caution is advised when Sildenafil Citrate is administered to patients taking an alpha-blocker, as the co-administration may lead to symptomatic hypotension in a few susceptible individuals. This is most likely to occur within 4 hours post Sildenafil Citrate dosing. In order to minimise the potential for developing postural hypotension, patients should be hemodynamically stable on alpha-blocker therapy prior to initiating Sildenafil Citrate treatment. Initiation of Sildenafil Citrate at a dose of 25 mg should be considered. In addition, physicians should advise patients what to do in the event of postural hypotensive symptoms.
Studies with human platelets indicate that Sildenafil Citrate potentiates the antiaggregatory effect of sodium nitroprusside in vitro. There is no safety information on the administration of Sildenafil Citrate to patients with bleeding disorders or active peptic ulceration. Therefore, Sildenafil Citrate should be administered to these patients only after careful benefit-risk assessment.
Sildenafil Citrate is not indicated for use by women.
Caution is required in patient with hepatic or severe renal impairment, and dosage reduction of Sildenafil Citrate may be necessary. Care is also needed in patients with anatomical deformation of the penis or haematological disorders that may predispose them to priapism. In the events of prolonged erection (for more than 4 hours), patients should seek medical assistance, as penile tissue damage and permanent loss of potency can occur. Patient is also advised to stop taking Sildenafil Citrate and seek medical advice in cases of sudden visual or hearing loss. Sildenafil Citrate should not be given to those with loss of vision in one eye caused by non-arteritic anterior ischaemic optic neuropathy (NAIO), regardless of whether this was in connection with previous phosphodiesterase type 5 inhibitors or not. Patient who experience dizziness or visual disturbances should not drive or operate hazardous machinery.
The safety of Sildenafil Citrate is uncertain in patients with severe hepatic impairment, bleeding disorders, active peptic ulceration, hypotension, hypertension, a recent history of stroke, myocardial infarction, or life-threatening arrhythmia, unstable angina, heart failure, or retinal disorders such as retinitis pigmentosa a majority of whom have genetic disorders of retinal phosphodiesterases). Licensed product information advises that it should not be used in these groups.
Cardiovascular Disease: For mention of a consensus statement on the use of Sildenafil Citrate in patients with cardiovascular disease, see previously mentioned text.
What happens if I miss a dose of Sildenafil Citrate?
Since Viagra is used as needed, you are not likely to miss a dose.
If you miss a dose of Sildenafil Citrate, take the missed dose as soon as you remember. Skip the missed dose if it is almost time for your next scheduled dose. Do not take extra medicine to make up the missed dose.
References
- DrugBank. "sildenafil". http://www.drugbank.ca/drugs/DB00203 (accessed September 17, 2018).
- MeSH. "Urological Agents". https://www.ncbi.nlm.nih.gov/mesh/68... (accessed September 17, 2018).
Reviews
Consumer reviews
There are no reviews yet. Be the first to write one! |
Information checked by Dr. Sachin Kumar, MD Pharmacology
